The differences between ACE inhibitor-treated and calcium channel blocker-treated hypertensive patients

Area of Science:

• Cardiology
• Pharmacology
• Hypertension Management

Background:

• Large-scale trials confirm blood pressure reduction with ACE inhibitors and CCBs lowers cardiovascular complications.
• Comparative trials between ACE inhibitors and CCBs have not shown definitive differences in cause-specific outcomes.

Purpose of the Study:

• To evaluate the comparative effectiveness of ACE inhibitors versus CCBs in managing hypertension and preventing cardiovascular and renal outcomes.
• To provide evidence-based recommendations for the routine therapy of hypertension.

Main Methods:

• Analysis of large-scale outcome trials comparing ACE inhibitors and CCBs.
• Review of studies in high-risk patient populations.
• Examination of long-term prospective observational data from major databases (Glasgow Blood Pressure Clinic, UK General Practice Research Database).

Main Results:

• ACE inhibitors demonstrate superiority over CCBs in protecting against cardiovascular events and renal disease, particularly in high-risk patients.
• Observational data strongly support an advantage of ACE inhibitors over CCBs regarding cardiovascular morbidity and mortality.
• No conclusive differences in cause-specific outcomes were found in earlier comparative trials.

Conclusions:

• Routine use of CCBs in hypertension therapy is not recommended.
• Wider use of ACE inhibitors, in conjunction with low-dose diuretics and beta blockers, is justified for hypertension management.
• ACE inhibitors offer significant benefits for cardiovascular and renal protection in hypertensive individuals.